News | July 16, 2022
Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
The company plans to execute both these tenders at their API manufacturing unit located at Savli, Gujarat, India.
Site Enhances New Modality CRDMO Platform Capacity for Customers
Govt committed to supporting pharma companies with industry-friendly policies
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
It is a two dose vaccine to be administered intramuscularly at 28 days apart
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Subscribe To Our Newsletter & Stay Updated
